Skip to main content

Sarah M. Kattakuzhy, MD

Academic Title:

Assistant Professor

Primary Appointment:

Medicine

Additional Title:

Director, Research Initiative on Infectious Disease and Substance Use Disorder, Baltimore Co-Director, Partnership for HIV/AIDS Progress Comorbidities Program

Location:

725 West Lombard St Baltimore, MD 21201

Phone (Primary):

443-691-4638

Fax:

301-451-5799

Education and Training

2000-2004                  BS, Biology and BS, Psychology, Virginia Commonwealth University

2005-2009                  MD, Eastern Virginia Medical School

2010-2012                  Residency, Internal Medicine, George Washington University 

2012-2013                  Chief Resident, Internal Medicine, George Washington University

Biosketch

I am an academic clinician investigator, with expertise in hepatitis C (HCV) and opioid use disorder (OUD). In 2013, I served as a clinician within the National Institute of Allergy and Infectious Disease, Laboratory of Immunoregulation clinic, gaining experience in advanced HIV treatment and the use of directly-acting antiviral therapy for HCV. In 2014, I transitioned to the Institute of Human Virology, where I now serve as Assistant Professor in the University of Maryland School of Medicine, and simultaneously lead the Partnership for HIV/AIDS Progress' (PFAP) Research Initiative in Infectious Disease and Substance Use (RIIS) as Baltimore Site Director.

In these positions, I provide both research-related and clinical care in community-based settings, serving an urban cohort representative of the HCV and OUD epidemics. I served as the lead investigator of the SYNERGY (G,H,F) study, evaluating the limits of short duration combination DAA therapy and predictors of successful treatment, and the ASCEND study, which explored the impact of provider type on HCV treatment outcomes in community-based settings.

My current research focus is on implementation-based improvements in the care of individuals with HCV and OUD. I serve as senior investigator of ANCHOR, a unique study designed to evaluate integrated HCV treatment, OUD treatment, and harm reduction in a high-risk population of persons with OUD, HCV, and active drug use. Finally, I serve as principal investigator of the HEAL Initiative-funded SEARCH investigations, which seek to evaluate ANS-6637, a potential novel therapeutic in the treatment of OUD.

Research/Clinical Keywords

Hepatitis C, Opioid Use Disorder, Implementation Science

Highlighted Publications

 

  1. Rosenthal ES, Silk R, Mathur P, Gross C, Eyasu R, Nussdorf L, Hill K, Brokus C, D'Amore A, Sidique N, Bijole P, Jones M, Kier R, McCullough D, Sternberg D, Stafford K, Sun J, Masur H, Kottilil S, Kattakuzhy S. Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs. Clin Infect Dis. 2020 Feb 3;PubMed PMID: 32009165.
  2. Schwetz TA, Calder T, Rosenthal E, Kattakuzhy S, Fauci AS. Opioids and Infectious Diseases: A Converging Public Health Crisis. J Infect Dis. 2019 Jul 2;220(3):346-349. PubMed PMID: 30941402; PubMed Central PMCID: PMC6941614.
  3. Kattakuzhy S, Gross C, Emmanuel B, Teferi G, Jenkins V, Silk R, Akoth E, Thomas A, Ahmed C, Espinosa M, Price A, Rosenthal E, Tang L, Wilson E, Bentzen S, Masur H, Kottilil S. Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial. Ann Intern Med. 2017 Sep 5;167(5):311-318. PubMed PMID: 28785771; PubMed Central PMCID: PMC5736381.
  4. Kattakuzhy S, Wilson E, Sidharthan S, Sims Z, McLaughlin M, Price A, Silk R, Gross C, Akoth E, McManus M, Emmanuel B, Shrivastava S, Tang L, Nelson A, Teferi G, Chavez J, Lam B, Mo H, Osinusi A, Polis MA, Masur H, Kohli A, Kottilil S. Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease. Clin Infect Dis. 2016 Feb 15;62(4):440-447. PubMed PMID: 26503379; PubMed Central PMCID: PMC4725378.

Additional Publication Citations

Wilson EM, Kattakuzhy S, Sidharthan S, Sims Z, Tang L, McLaughlin M, Price A, Nelson A, Silk R, Gross C, Akoth E, Mo H, Subramanian GM, Pang PS, McHutchison JG, Osinusi A, Masur H, Kohli A, Kottilil S. Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens. Clin Infect Dis. 2016 Feb 1;62(3):280-288. PubMed PMID: 26521268; PubMed Central PMCID: PMC4706633.

Faldetta KF, Kattakuzhy S, Wang HW, Sereti I, Sheikh V. Cytomegalovirus immune reconstitution inflammatory syndrome manifesting as acute appendicitis in an HIV-infected patient. BMC Infect Dis. 2014 Jun 9;14:313. PubMed PMID: 24910267; PubMed Central PMCID: PMC4057562.

Hadigan C, Kattakuzhy S. Diabetes mellitus type 2 and abnormal glucose metabolism in the setting of human immunodeficiency virus. Endocrinol Metab Clin North Am. 2014 Sep;43(3):685-96. PubMed PMID: 25169561; PubMed Central PMCID: PMC4159723.

    Wilson EM, Rosenthal ES, Kattakuzhy S, Tang L, Kottilil S. Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C. Clin Microbiol Rev. 2017 Jan;30(1):23-42. PubMed PMID: 27795306; PubMed Central PMCID: PMC5217793.

      Tang LS, Masur J, Sims Z, Nelson A, Osinusi A, Kohli A, Kattakuzhy S, Polis M, Kottilil S. Safe and effective sofosbuvir-based therapy in patients with mental health disease on hepatitis C virus treatment. World J Hepatol. 2016 Nov 8;8(31):1318-1326. PubMed PMID: 27872683; PubMed Central PMCID: PMC5099584.

      Gross C, Akoth E, Price A, Kattakuzhy S, Silk R, Rosenthal E. HIV/HCV Co-infection: Overcoming Barriers to Treatment. J Assoc Nurses AIDS Care. 2016 Jul-Aug;27(4):524-9. PubMed PMID: 26996983.

      Akoth E, Gross C, Silk R, Rosenthal E, Kattakuzhy SA Practical Approach and Model of Care for HCV Treatment With Direct Acting Antivirals in an Urban Setting. J Assoc Nurses AIDS Care. 2017 Sep - Oct;28(5):680-684. doi: 10.1016/j.jana.2017.04.007. Epub 2017 Apr 26. PubMed PMID: 28506435.

      Research Interests

      My current research focus is on implementation-based improvements in the care of individuals with HCV and OUD. I serve as senior investigator of ANCHOR, a unique study designed to evaluate integrated HCV treatment, OUD treatment, and harm reduction in a high-risk population of persons with OUD, HCV, and active drug use. Finally, I serve as principal investigator of the HEAL Initiative-funded SEARCH investigations, which seek to evaluate ANS-6637, a potential novel therapeutic in the treatment of OUD.

      Clinical Specialty Details

      Internal Medicine

      Grants and Contracts

       

       

      In the News